A Phase II/III Study to Compare IBB0979 in Combination With Topotecan Versus Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Latest Information Update: 30 Jul 2025
At a glance
- Drugs IBB-0979 (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors SUNHO (China) BioPharmaceutical
Most Recent Events
- 30 Jul 2025 New trial record